Literature DB >> 16261381

Computational studies on class I ribonucleotide reductase: understanding the mechanisms of action and inhibition of a cornerstone enzyme for the treatment of cancer.

Susana Pereira1, Nuno M F S A Cerqueira, Pedro Alexandrino Fernandes, Maria João Ramos.   

Abstract

This review provides a synthesis of recent work, using computational methods, on the action and inhibition mechanisms of class I ribonucleotide reductase (RNR). This enzyme catalyzes the rate-limiting step of the pathway for the synthesis of DNA monomers and, therefore, has long been regarded as an important target for therapies aiming to control pathologies that depend strongly on DNA replication. In fact, over the last years, several molecules, which are able to impair RNR activity by different mechanisms, have been applied effectively in anti-cancer, anti-viral and anti-parasite therapies. A better understanding of the chemical mechanisms involved in normal catalysis and in inhibition of the enzyme is important for the rational design of more specific and effective inhibitor compounds. To achieve this goal, computational methods, particularly quantum chemical calculations, have been used more and more frequently. The ever-growing capabilities of these methods together with undeniable advantages make it a stimulating area for research purposes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16261381     DOI: 10.1007/s00249-005-0026-6

Source DB:  PubMed          Journal:  Eur Biophys J        ISSN: 0175-7571            Impact factor:   1.733


  33 in total

Review 1.  Quantum chemical studies of intermediates and reaction pathways in selected enzymes and catalytic synthetic systems.

Authors:  Louis Noodleman; Timothy Lovell; Wen-Ge Han; Jian Li; Fahmi Himo
Journal:  Chem Rev       Date:  2004-02       Impact factor: 60.622

2.  Three-dimensional structure of the free radical protein of ribonucleotide reductase.

Authors:  P Nordlund; B M Sjöberg; H Eklund
Journal:  Nature       Date:  1990-06-14       Impact factor: 49.962

3.  Theoretical Model Studies of the Iron Dimer Complex of MMO and RNR.

Authors:  Per E. M. Siegbahn
Journal:  Inorg Chem       Date:  1999-06-14       Impact factor: 5.165

4.  Theoretical studies on the mode of inhibition of ribonucleotide reductase by 2'-substituted substrate analogues.

Authors:  Pedro Alexandrino Fernandes; Maria João Ramos
Journal:  Chemistry       Date:  2003-12-05       Impact factor: 5.236

5.  Structure of ribonucleotide reductase protein R1.

Authors:  U Uhlin; H Eklund
Journal:  Nature       Date:  1994-08-18       Impact factor: 49.962

Review 6.  Gemcitabine in breast cancer: future directions.

Authors:  Debu Tripathy
Journal:  Clin Breast Cancer       Date:  2002-05       Impact factor: 3.225

7.  Human ribonucleotide reductase. Activation and inhibition by analogs of ATP.

Authors:  J A Harrington; T Spector
Journal:  Biochem Pharmacol       Date:  1991-07-25       Impact factor: 5.858

8.  Class I ribonucleotide reductase revisited: the effect of removing a proton on Glu441.

Authors:  Vladimir Pelmenschikov; Kyung-Bin Cho; Per E M Siegbahn
Journal:  J Comput Chem       Date:  2004-02       Impact factor: 3.376

9.  Electronic and spectroscopic studies of the non-heme reduced binuclear iron sites of two ribonucleotide reductase variants: comparison to reduced methane monooxygenase and contributions to O2 reactivity.

Authors:  Pin-Pin Wei; Andrew J Skulan; Natasa Mitić; Yi-Shan Yang; Lana Saleh; J Martin Bollinger; Edward I Solomon
Journal:  J Am Chem Soc       Date:  2004-03-31       Impact factor: 15.419

Review 10.  Gemcitabine (Gemzar) in non-small cell lung cancer.

Authors:  Christian Manegold
Journal:  Expert Rev Anticancer Ther       Date:  2004-06       Impact factor: 4.512

View more
  1 in total

1.  Targeting the Large Subunit of Human Ribonucleotide Reductase for Cancer Chemotherapy.

Authors:  Sanath R Wijerathna; Md Faiz Ahmad; Hai Xu; James W Fairman; Andrew Zhang; Prem Singh Kaushal; Qun Wan; Jianying Kiser; Chris G Dealwis
Journal:  Pharmaceuticals (Basel)       Date:  2011-10-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.